MA29677B1 - Medicament prophylactique ou therapeutique contre la depression ou la nevrose d'angoisse - Google Patents

Medicament prophylactique ou therapeutique contre la depression ou la nevrose d'angoisse

Info

Publication number
MA29677B1
MA29677B1 MA30311A MA30311A MA29677B1 MA 29677 B1 MA29677 B1 MA 29677B1 MA 30311 A MA30311 A MA 30311A MA 30311 A MA30311 A MA 30311A MA 29677 B1 MA29677 B1 MA 29677B1
Authority
MA
Morocco
Prior art keywords
prophylactic
depression
therapeutic drug
nevrose
angoisse
Prior art date
Application number
MA30311A
Other languages
English (en)
Inventor
Keisuke Hirai
Masaomi Miyamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37073564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29677(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA29677B1 publication Critical patent/MA29677B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)

Abstract

La présente invention divulgue un médicament prophylactique ou thérapeutique contre la dépression ou la névrose d'angoisse, contenant le (S)-N-[2-(l,6,7,8-tétrahydro-2H-indéno[5,4-b]furane-8-yl)éthyl]propionamide.
MA30311A 2005-04-04 2007-10-25 Medicament prophylactique ou therapeutique contre la depression ou la nevrose d'angoisse MA29677B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005107674 2005-04-04

Publications (1)

Publication Number Publication Date
MA29677B1 true MA29677B1 (fr) 2008-08-01

Family

ID=37073564

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30311A MA29677B1 (fr) 2005-04-04 2007-10-25 Medicament prophylactique ou therapeutique contre la depression ou la nevrose d'angoisse

Country Status (23)

Country Link
US (1) US20090042861A1 (fr)
EP (1) EP1867641A4 (fr)
JP (1) JP5259181B2 (fr)
KR (1) KR20070118103A (fr)
CN (1) CN101189219A (fr)
AR (1) AR054435A1 (fr)
AU (1) AU2006231752B2 (fr)
BR (1) BRPI0607684A2 (fr)
CA (1) CA2602267A1 (fr)
CL (1) CL2009000980A1 (fr)
CR (1) CR9385A (fr)
GE (1) GEP20105001B (fr)
IL (1) IL186049A0 (fr)
MA (1) MA29677B1 (fr)
MY (1) MY142214A (fr)
NO (1) NO20075599L (fr)
NZ (1) NZ561677A (fr)
PE (1) PE20061355A1 (fr)
RU (1) RU2413510C2 (fr)
TW (1) TWI391132B (fr)
UA (1) UA89397C2 (fr)
WO (1) WO2006107019A1 (fr)
ZA (1) ZA200708445B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2507517T3 (es) * 2008-01-31 2014-10-15 Takeda Pharmaceutical Company Limited Agente profiláctico o terapéutico para trastorno de déficit de atención con hiperactividad
US8426461B2 (en) 2011-01-17 2013-04-23 Takeda Pharmaceutical Company Limited Orally dispersible tablet
EP2665465A1 (fr) * 2011-01-17 2013-11-27 Takeda Pharmaceutical Company Limited Comprimé dispersible par voie orale
JP6061924B2 (ja) * 2011-10-14 2017-01-18 武田薬品工業株式会社 口腔内分散性製剤
CN102718675B (zh) * 2012-06-07 2015-03-25 上海右手医药科技开发有限公司 阿戈美拉汀甲磺酸复合物及其制备方法
RU2571546C1 (ru) * 2014-07-14 2015-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ дифференцированной диагностики и терапии синдрома ночной еды
US20200022951A1 (en) 2017-03-30 2020-01-23 Jose Eduardo PENELLO TEMPORÃO Multivitamin composition for improving verbal fluency, decreasing performance anxiety symptoms and method for preparing same
CN108451917A (zh) * 2018-03-22 2018-08-28 仁和堂药业有限公司 高稳定性米安色林制剂的制备方法
CN113908165A (zh) * 2020-07-10 2022-01-11 上海日馨医药科技股份有限公司 一种药物组合物及其应用
WO2025018810A1 (fr) * 2023-07-18 2025-01-23 주식회사 지오비스타 Composition pour la prévention ou le traitement de maladies mentales ou de troubles comportementaux chez les animaux

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
ATE250052T1 (de) * 1994-06-10 2003-10-15 Smithkline Beecham Plc Benzopyrane und deren verwendung als heilmittel
US5780470A (en) * 1995-06-02 1998-07-14 Bristol-Myers Squibb Company Melatonergic indanyl piperazines
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
CA2241666C (fr) * 1996-03-08 2007-11-06 Takeda Chemical Industries, Ltd. Composes tricycliques, leur production et leur utilisation
DE69910795T2 (de) * 1998-06-09 2004-06-17 Takeda Chemical Industries, Ltd. Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
HUP0301719A2 (hu) * 2000-06-27 2003-09-29 Taisho Pharmaceutical Co., Ltd. Szorongásos neurózis vagy depresszió kezelésére szolgáló gyógyszerkészítmény és piperazinszármazékok
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
WO2003022283A1 (fr) * 2001-09-13 2003-03-20 Schering Corporation Combinaison d'un antagoniste du recepteur d'adenosine a2a et d'un antidepresseur ou d'un anxiolytique
US20070088079A1 (en) * 2005-09-20 2007-04-19 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for sleep disorder

Also Published As

Publication number Publication date
ZA200708445B (en) 2009-03-25
IL186049A0 (en) 2008-02-09
UA89397C2 (ru) 2010-01-25
RU2007140986A (ru) 2009-05-20
US20090042861A1 (en) 2009-02-12
CL2009000980A1 (es) 2009-08-14
MY142214A (en) 2010-11-15
AR054435A1 (es) 2007-06-27
NZ561677A (en) 2011-02-25
BRPI0607684A2 (pt) 2009-09-22
CR9385A (es) 2007-12-07
CN101189219A (zh) 2008-05-28
EP1867641A4 (fr) 2010-01-13
AU2006231752B2 (en) 2012-03-01
TWI391132B (zh) 2013-04-01
AU2006231752A1 (en) 2006-10-12
CA2602267A1 (fr) 2006-10-12
PE20061355A1 (es) 2007-01-15
KR20070118103A (ko) 2007-12-13
NO20075599L (no) 2007-12-19
TW200719885A (en) 2007-06-01
GEP20105001B (en) 2010-06-10
JPWO2006107019A1 (ja) 2008-09-25
WO2006107019A1 (fr) 2006-10-12
EP1867641A1 (fr) 2007-12-19
RU2413510C2 (ru) 2011-03-10
JP5259181B2 (ja) 2013-08-07

Similar Documents

Publication Publication Date Title
EA200400481A1 (ru) Применение флибансерина для лечения половых расстройств
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
WO2007010034A3 (fr) Copolymere ampholyte, sa production et son utilisation
PT1506185E (pt) Compostos novos e sua utilizacao
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
FR2909867B3 (fr) Capsule remplie d'un medicament, en particulier d'un medicament inhalable.
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
MXPA04002510A (es) Combinacion de opioides selectos con antagonistas de muscarina para tratamiento de incontinencia urinaria.
ITMO20040351A1 (it) ''confezione per prodotti framaceutici,medicinali o simili,particolarmente fitofarmaci o fitosanitari''.
MY148459A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
EA200501697A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
HRP20040186B1 (en) Use of lhrh-antagonists for the improvement of t-cell mediated immunity
PL1713438T3 (pl) Mydło lecznicze
GEP20084546B (en) Novel association consisting of an anti-atherothrombotic agent and of platelet antiaggregating agent
UY27376A1 (es) Formulación de medicamento que contiene un antagonista de ltb4
WO2005060978A3 (fr) Formulations a base de polymethaphosphate servant au traitement d'arthropathies microcristallines
NO20075600L (no) Profylaktisk eller terapeutisk middel mot nattlig atferdsforstyrrelse assosiert med demens
FR2885812B1 (fr) Medicament a base de laminarine ou d'oligolaminarines pour le traitement de la septicemie et du choc septique
ITMI20041822A1 (it) "agente terapeutico utile per il trattamento di neoplasie plasmacellulari"
MX2007012219A (es) Medida de prevencion o remedio para neurosis paro depresion o ansiedad.
ITVI20040153A1 (it) Dispositivo di gioco, particolarmente per la ricerca dell'equilibrio statico di un corpo
AU2003283508A1 (en) .pharmaceutical composition comprising htless thansbgreater than4less than/sbgreater thandless thanspgreater than100less than/spgreater thana receptors, and therapeutic uses thereof
SI1532124T1 (sl) Uporaba nitrilnih derivatov kot zdravila
RU2004113222A (ru) Применение препарата "реамберин-1,5% для инфузий" в качестве средства снижения вязкости крови (плазмы)